Opicapone Market

The Opicapone market is projected to grow at a CAGR of 6.2% between 2025 and 2035, driven by the increasing global prevalence of Parkinson’s disease and the demand for more effective adjunctive therapies. Opicapone is a peripherally selective, long-acting catechol-O-methyltransferase (COMT) inhibitor used in combination with levodopa to manage end-of-dose motor fluctuations in Parkinson’s patients. It offers a favorable pharmacokinetic profile with once-daily dosing and reduced risk of hepatotoxicity compared to older COMT inhibitors. Its proven efficacy in extending the duration of levodopa’s action has made it an essential part of advanced Parkinson’s disease management.

Geographically, Europe currently dominates the Opicapone market, with early approvals and wide adoption in countries such as Germany, Spain, and the UK, where national guidelines endorse its use. North America is witnessing growing demand, particularly in the U.S., following regulatory approvals and expanded neurologist-led management of motor complications. The Asia-Pacific region is emerging as a high-growth zone, driven by aging populations, rising awareness of neurodegenerative disorders, and improved neurologic care infrastructure in countries like Japan, South Korea, and China. Latin America and the Middle East & Africa are also showing increasing adoption due to rising diagnosis rates and improved access to advanced therapies through hospital networks and specialty care centers.

The market remains positive as the Parkinson’s treatment landscape continues to evolve toward individualized combination therapy. Opicapone is expected to maintain strong demand due to its ability to enhance levodopa efficacy without a significant added pill burden.